Is hypercholesterolemia a risk factor and should it be treated in the elderly?

American Journal of Health Promotion

Volumn 14, Issue 6, 2000, Pages 347-356

  Hall, K M ^a   Luepker, R V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cholesterol; Coronary Heart Disease; Elderly; Prevention

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEZAFIBRATE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; PRAVASTATIN; TRIACYLGLYCEROL; URIC ACID;

AGED; ARTICLE; CLINICAL TRIAL; DIET; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; RISK FACTOR;

EID: 0033856805     PISSN: 08901171     EISSN: None     Source Type: Journal    
DOI: 10.4278/0890-1171-14.6.347     Document Type: Article

References (59)

1. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
2. Epidemiology of coronary heart disease: The Framingham study
3. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study
4. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study
5. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
6. Mechanistic studies of high-density lipoproteins
7. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
8. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop
9. Triglycerides and coronary risk in women and the elderly
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
12. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
13. Epidemiological aspects of cardiovascular disease in the elderly
14. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults
15. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease
16. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study
17. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study
18. Determinants of change in total cholesterol and HDL-C with age: The Framingham Study
19. Do coronary heart disease risk factors measured in the elderly have the same predictive roles as in the middle aged? Comparisons of relative and attributable risks
20. Comparison of risk profiles for cardiovascular events: Implications for prevention
21. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts
22. Ischemic heart disease risk factors after age 50
23. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data
24. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP)
25. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years
26. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons
27. 41-month follow-up of risk factors correlated with new coronary events in 708 elderly patients
28. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?
29. Systematic underestimation of association between serum cholesterol concentration and ischemic heart disease in observational studies: Data from the BUPA study
30. Is the serum cholesterol-coronary heart disease relationship modified by activity level in older persons?
31. How to read a paper: The MEDLINE database
32. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials
33. Lipid metabolism and cardiovascular risk: Should hypercholesterolemia be treated in the elderly?
34. The value of lowering cholesterol after myocardial infarction
35. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
36. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
37. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
38. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
39. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
40. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
41. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
42. Prospective meta-analysis of cholesterol-lowering studies: The Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) collaboration
43. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study
44. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
45. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
46. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
47. Design of the Women's Health Initiative clinical trial and observational study
48. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
49. Screening for coronary heart disease in elderly men based on current and past cholesterol levels
50. To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program
51. The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines
52. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
53. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women
54. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
55. Physical activity and coronary heart disease in middle-aged and elderly men: The Honolulu Heart Program